Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
NEW YORK, May 02, 2018 -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced that management will present a corporate overview at Deutsche Bank’s 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 10:40 a.m. ET.
A live audio webcast of the presentation can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the company's website for two weeks following the live presentation.
About Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome in 2017 and completed a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of epileptic encephalopathies and in 2017 initiated a Phase 1b/2a trial of OV935.
For more information on Ovid, please visit http://www.ovidrx.com/.
Contacts:
Ovid Therapeutics Inc.
Lora Pike
Senior Director, Investor Relations & Public Relations
[email protected]
OR
Investors:
Burns McClellan
Steve Klass, 212-213-0006
[email protected]
